Alector, Inc. (ALEC) Q2 2026 Earnings: Revenue $3.3M (-57.8%)
ALEC — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop
Alector's Q2 2026 net loss narrowed 24.7% to $23.0M on a 34% cut in operating costs, but revenue fell 57.8% to $3.3M and GSK is ending the partnership, leaving $172.8M of cash to fund a preclinical pipeline.
Revenue
$3.3M
-57.8% YoY
Net income
-$23M
+24.7% YoY
Diluted EPS
$-0.21
+30.0% YoY
This period vs a year ago
Same period last year
This period
Revenue▼-57.8%
≈$7.9M
$3.3M
Year-ago figures (≈) are worked out from the growth rate the company reported. Each row has its own scale.
Alector's Q2 2026: a smaller loss from deep cuts, as its last partner walks away
Alector, a San Francisco biotech developing drugs for brain diseases such as Alzheimer's and Parkinson's, has no approved products and earns no sales. Its only revenue is "collaboration revenue" — money from partners booked gradually as joint research is done. In the second quarter of 2026 (April–June) that revenue fell 57.8% to $3.3 million, while the net loss narrowed 24.7% to $23.0 million because the company spent a third less after two rounds of layoffs. The bigger news sits outside the income statement: in April, GSK stopped the jointly run Phase 2 Alzheimer's trial of nivisnebart after an interim check found it was unlikely to work, and on July 6, 2026 GSK gave notice ending the whole partnership, effective January 2, 2027. With AbbVie already gone since February 2025, Alector is now a self-funded preclinical company — its next drug is not expected to enter human testing until early 2027.
At a glance
$172.8 million in cash and investments at June 30, 2026 (down from $256.0 million at the start of the year) — management says this lasts "at least through 2027", and the company has no debt after repaying its $10.4 million Hercules loan on July 8.
Total operating expenses down 34.0% to $27.7 million — mostly lower staff costs after the company cut about 47% of its workforce in October 2025.
$162.9 million of deferred revenue still on the balance sheet — cash GSK paid up front in 2021–22 that hasn't yet been counted as revenue. With the partnership ending, how and when that balance is released is the biggest accounting swing ahead.
Key figures
Metric
Q2 2026
Q2 2025
YoY Change
Collaboration revenue
$3.3M
$7.9M
Read 0 community reports on Alector, Inc., or write your own.Write a report
Operating margin is left out on purpose: with $3.3 million of revenue against $27.7 million of costs it works out to about -735%, a number that says nothing useful about a company that doesn't sell anything yet.
Takeaway: Alector's loss is shrinking because it is doing less, not because anything is working better — the two partner-funded programs that paid for the company (latozinemab and nivisnebart) have both failed, GSK is leaving, and everything now rests on a preclinical pipeline whose first human trial is targeted for April 2027, funded by roughly $162 million of cash after the loan payoff.
Where the money went
Revenue. The $4.6 million drop in collaboration revenue was "primarily due to a lower revenue recognized for the AL101 AD program" — AL101 being nivisnebart. Alector books GSK revenue in proportion to how much of a program's total expected cost has been spent, so as the Alzheimer's trial wound down after the futility finding, less revenue was recognized. For the first half of 2026 revenue was $4.4 million, down from $11.5 million.
Research and development fell $8.1 million to $19.5 million, "mainly due to a decrease in personnel-related costs as a result of the reductions in force as well as a decrease in facilities and other expenses." The program-level breakdown shows where spending moved:
R&D line (Q2)
2026
2025
AL037/AL137 (anti-amyloid antibody with brain carrier)
$5.0M
$0
Other programs (incl. siRNA work)
$3.2M
$5.0M
Latozinemab (wind-down)
$1.4M
$0.9M
Nivisnebart (wind-down)
$0.7M
$0.9M
AL002 (discontinued)
$0
$2.0M
R&D personnel (incl. stock-based pay)
$5.4M
$12.1M
Facilities and other unallocated
$3.9M
$6.7M
The direction is clear: money has moved off the old clinical programs and onto AL137, which became the single biggest direct program line at $5.0 million for the quarter ($8.0 million year to date).
General and administrative costs fell $6.1 million to $8.3 million, again "mainly driven by a decrease in personnel-related costs."
Interest income — the main item in "other income" — fell to $1.5 million from $3.6 million because there is simply less money in the bank to earn interest on.
What the headline numbers hide
The R&D cut is bigger than it looks. Under the GSK agreement, GSK reimbursed a share of joint development costs, and those reimbursements were netted against R&D expense. In Q2 2025 that lowered R&D by $6.1 million; in Q2 2026 the cost-sharing went the other way and added $0.3 million. So on a like-for-like basis, before partner reimbursements, Alector's own R&D spending fell by roughly $14.5 million, not $8.1 million. The flip side: that partner subsidy is gone for good.
Cash burn was much heavier than the loss. For the first half, the net loss was $45.9 million but cash used in operations was $84.0 million. The gap is mostly settling old obligations: a $15.4 million reduction in the refund liability owed to GSK (the cost-share Alector had agreed to fund for the nivisnebart trial — now down to zero), a $13.6 million fall in amounts payable to GSK, and a $13.8 million fall in accrued liabilities and clinical supply costs, which includes severance from the October 2025 layoffs (paid out and completed in the first half of 2026, per the filing). These are largely one-time, so the second-half burn should run closer to the underlying loss — but the filing doesn't give a forecast, so that is our inference.
Stock-based pay fell sharply, from $7.1 million to $2.6 million in the quarter. That is a non-cash cost, so part of the narrower loss is lower paper expense rather than cash saved.
Negative shareholders' equity (-$10.0 million) is an accounting artifact, not insolvency. Total liabilities ($212.8 million) exceed total assets ($202.9 million) only because of the $162.9 million deferred-revenue balance — GSK's upfront payments not yet booked as revenue. The refund liability to GSK stands at zero, so this is not a bill Alector must pay back in cash. The filing says the balance is recognized over the research period "or earlier upon extinguishment of the related performance obligations"; with the agreement terminating January 2, 2027, a large non-cash revenue figure could appear in a coming quarter. If it does, it will not mean the business improved — treat any reported "profit" from it accordingly.
The loan payoff trims the runway. The $172.8 million figure is before the July 8 repayment of $10.4 million of principal plus interest and end-of-term and prepayment charges, so usable cash is closer to $162 million. Removing the lender's liens does give the company more flexibility.
No restructuring reversal is flattering the quarter. The company reversed less than $0.1 million of previously booked layoff costs in Q2 (about $0.4 million for the half-year), so the expense decline reflects genuinely lower running costs.
The pipeline that now has to carry the company
Everything clinical-stage is gone: latozinemab failed its Phase 3 trial in frontotemporal dementia in October 2025, nivisnebart was stopped for futility in April 2026, and AL002 was discontinued earlier. What is left is built on Alector's "ABC" (Alector Brain Carrier) technology — a way of attaching drugs to a molecule that hitches a ride on the transferrin receptor, a natural transport route across the blood-brain barrier (the protective lining that keeps most drugs out of the brain).
AL137 — an antibody that targets a specific form of amyloid plaque (pyroglutamate-3 amyloid beta) in Alzheimer's, designed to be given as an under-the-skin injection. Alector picked it over AL037 (now the backup). The company targets an IND — the application to the FDA needed to start human trials — in the first quarter of 2027, and first dosing of a person in Australia "no later than April 2027."
AL164 (from AL064) — an siRNA (a molecule that silences a specific gene) aimed at reducing tau protein in Alzheimer's and related diseases; now entering IND-enabling studies.
AL050 — an enzyme-replacement therapy for Parkinson's disease and Lewy body dementia in patients with GBA1 gene mutations; chosen as lead candidate, but the company says it "continue[s] to evaluate our timeline to the clinic."
Earlier siRNA programs against alpha-synuclein (Parkinson's) and NLRP3 (inflammation) are still working toward lead selection.
Outlook
Management's only financial guidance is runway: existing cash is expected to fund operations "at least through 2027." That window covers the planned AL137 IND and first-in-human dosing, but not a meaningful efficacy readout, which would come later. The company has put fundraising tools in place — a $400 million shelf registration effective April 30, 2026 and a new $125 million at-the-market share-sale agreement with TD Cowen signed May 7, 2026 (unused as of June 30) — and says it "will need to obtain substantial additional funding in the future." The risk-factor section also flags that the stock has traded below Nasdaq's $1.00 minimum bid at points and that its market value has at times been below its cash holdings.
Our read: the cost base is now roughly $28 million a quarter in operating expenses with almost no partner revenue coming in after GSK leaves, so the cash pile should shrink by something like $20–25 million a quarter once the one-time payouts are behind it — consistent with the "through 2027" claim but leaving little room for a delayed IND or a costly first trial without new money or a new partner. For shareholders, the realistic near-term catalysts are a new partnership around the ABC platform or the AL137 IND filing; the likely headwind is dilution from share sales. Watch three things in the Q3 10-Q (expected early November 2026): how the $162.9 million of deferred revenue is treated after GSK's notice, whether quarterly operating cash burn drops toward the size of the loss, and any change to the Q1 2027 AL137 IND target.